Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.
Opinion
· 16h · on MSN
The Bears seemingly won big with Ben Johnson hire – but he's still a total unknown as head coach
Of course, the Bears wanted Ben Johnson. Surprisingly, he wanted them even more
Johnson wasn't scared off by coaching in the ultra-competitive NFC North and said his family is excited about living in the Chicago area.
· 1d · on MSN
Ben Johnson "cannot wait to get to work" coaching "absolutely loaded" Bears team
New head coach Ben Johnson believes the team could turn it around quickly and make the playoffs in his first season.
· 11h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
Whether Ben Johnson and Ryan Poles think it's a top priority isn't known but the new Bears coach threw out a position they could stand to 'augment.'
With Ben Johnson off to be the head coach of the Chicago Bears, the Lions will need a new voice to lead the offense. Johnson's move to the division rival has frustrated some fans, and left pundits wondering if there was friction amongst Dan Campbell's coaching staff.
16h
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee
Caleb Williams is the biggest reason Ben Johnson took the Bears' head coaching job. Here's why Johnson is so high on the young QB.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback